Cargando…
A Phase-2 NIH-sponsored Randomized Clinical Trial of Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach Significance for Its Endpoints: End of Story? Not So Fast!
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Thoracic Society
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650784/ https://www.ncbi.nlm.nih.gov/pubmed/33856964 http://dx.doi.org/10.1164/rccm.202103-0612ED |
| _version_ | 1784611272123219968 |
|---|---|
| author | Zhang, Yongneng Michelakis, Evangelos D. |
| author_facet | Zhang, Yongneng Michelakis, Evangelos D. |
| author_sort | Zhang, Yongneng |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8650784 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | American Thoracic Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86507842021-12-08 A Phase-2 NIH-sponsored Randomized Clinical Trial of Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach Significance for Its Endpoints: End of Story? Not So Fast! Zhang, Yongneng Michelakis, Evangelos D. Am J Respir Crit Care Med Editorials American Thoracic Society 2021-03-30 /pmc/articles/PMC8650784/ /pubmed/33856964 http://dx.doi.org/10.1164/rccm.202103-0612ED Text en Copyright © 2021 by the American Thoracic Society https://creativecommons.org/licenses/by-nc-nd/4.0/This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/). For commercial usage and reprints, please contact Diane Gern (dgern@thoracic.org). |
| spellingShingle | Editorials Zhang, Yongneng Michelakis, Evangelos D. A Phase-2 NIH-sponsored Randomized Clinical Trial of Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach Significance for Its Endpoints: End of Story? Not So Fast! |
| title | A Phase-2 NIH-sponsored Randomized Clinical Trial of Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach Significance for Its Endpoints: End of Story? Not So Fast! |
| title_full | A Phase-2 NIH-sponsored Randomized Clinical Trial of Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach Significance for Its Endpoints: End of Story? Not So Fast! |
| title_fullStr | A Phase-2 NIH-sponsored Randomized Clinical Trial of Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach Significance for Its Endpoints: End of Story? Not So Fast! |
| title_full_unstemmed | A Phase-2 NIH-sponsored Randomized Clinical Trial of Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach Significance for Its Endpoints: End of Story? Not So Fast! |
| title_short | A Phase-2 NIH-sponsored Randomized Clinical Trial of Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach Significance for Its Endpoints: End of Story? Not So Fast! |
| title_sort | phase-2 nih-sponsored randomized clinical trial of rituximab in scleroderma-associated pulmonary arterial hypertension did not reach significance for its endpoints: end of story? not so fast! |
| topic | Editorials |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650784/ https://www.ncbi.nlm.nih.gov/pubmed/33856964 http://dx.doi.org/10.1164/rccm.202103-0612ED |
| work_keys_str_mv | AT zhangyongneng aphase2nihsponsoredrandomizedclinicaltrialofrituximabinsclerodermaassociatedpulmonaryarterialhypertensiondidnotreachsignificanceforitsendpointsendofstorynotsofast AT michelakisevangelosd aphase2nihsponsoredrandomizedclinicaltrialofrituximabinsclerodermaassociatedpulmonaryarterialhypertensiondidnotreachsignificanceforitsendpointsendofstorynotsofast AT zhangyongneng phase2nihsponsoredrandomizedclinicaltrialofrituximabinsclerodermaassociatedpulmonaryarterialhypertensiondidnotreachsignificanceforitsendpointsendofstorynotsofast AT michelakisevangelosd phase2nihsponsoredrandomizedclinicaltrialofrituximabinsclerodermaassociatedpulmonaryarterialhypertensiondidnotreachsignificanceforitsendpointsendofstorynotsofast |